Sjogren's Syndrome


Abatacept Fails Clinical Trial for Sjögren’s Syndrome

March 24, 2020

The use of abatacept did not lead to significant improvements in the disease status of patients with primary Sjögren's syndrome and in fact, it was essentially no better than placebo treatment, shows the first randomized, double-blind trial on abatacept for Sjögren’s.

Secondary Sjögren’s Syndrome in Lupus Increases with Age

October 07, 2019

Sjögren’s syndrome secondary to systemic lupus erythematosus (SLE) rises in frequency with age, affects around one-quarter of all people with systemic lupus, and, despite less internal organ involvement than in systemic lupus without Sjögren’s syndrome, is marked by a systemic inflammatory state with high levels of pro-inflammatory cytokines, say researchers writing in The Journal of Rheumatology  this month.

Sjögren’s Patients Could Benefit from Lupus Drug

August 20, 2015

B-cells that are active in lupus may also play a role in Sjögren’s syndrome. A new study finds that the same B-cell depleter drug, belimumab (Benlysta) approved for lupus, may also benefit Sjögren’s patients.

Post-Op VTE Risk in Rheumatic Disease Traces to Clotting Issues

March 26, 2015

The increased risk for venous thromoboembolism after surgery among patients with rheumatic disease appears to trace to those conditions with a clotting component. However, joint surgery in general has a high risk of this complication.